ArticleJournal of Alzheimer's disease reports2023

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.

Brian A Willis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.